Over the past 20 years our research has contributed to transforming the lives of patients with diseases of the blood, including non-Hodgkin lymphoma. We have a dedicated, ongoing programme of ...

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

The rate of non-Hodgkin's lymphoma has nearly doubled since the 1970s, but advances in treatments are offering new hope. Laura Colton Tepper had just endured her second round of chemotherapy for ...

However, the five-year survival rate for all stages of non-Hodgkin lymphoma is 65%, with regional lymphomas (like stage 3) at 74%. “In general, the goal of treatment is [a cure],” Bond said.

Medically reviewed by Gagandeep Brar, MD Leukemias and lymphomas are often grouped together because they are both blood-related cancers that originate in lymphocytes. However, leukemia originates in ...

The five-year relative survival rate for stage 4 Hodgkin lymphoma is 81 percent, and 64 percent for stage 4 non-Hodgkin lymphoma. Everyday Health follows strict sourcing guidelines to ensure the ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin's lymphoma (NHL) confined to the nervous system. The disease is managed quite differently from other primary brain ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...